At the time of writing, Biocryst Pharmaceuticals Inc [BCRX] stock is trading at $10.07, down -2.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCRX shares have gain 2.23% over the last week, with a monthly amount glided 28.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] stock has seen the most recent analyst activity on April 29, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $20. Previously, Wedbush started tracking the stock with Outperform rating on February 25, 2025, and set its price target to $15. RBC Capital Mkts upgraded its rating to a Outperform and increased its price target to $10 on September 18, 2023. Jefferies upgraded its rating to a Buy but $11 remained the price target by the analyst firm on August 04, 2023. BofA Securities upgraded its rating to Buy for this stock on July 13, 2023, but kept the price target unchanged to $10. In a note dated February 22, 2023, Needham upgraded an Buy rating on this stock but restated the target price of $14.
For the past year, the stock price of Biocryst Pharmaceuticals Inc fluctuated between $5.92 and $11.11. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] shares were valued at $10.07 at the most recent close of the market. An investor can expect a potential return of 58.89% based on the average BCRX price forecast.
Analyzing the BCRX fundamentals
According to Biocryst Pharmaceuticals Inc [NASDAQ:BCRX], the company’s sales were 503.49M for trailing twelve months, which represents an 56.89% jump. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at 0.07%, Pretax Profit Margin comes in at -0.1%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is 0.11 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.76.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Biocryst Pharmaceuticals Inc [NASDAQ:BCRX] has a current ratio of 2.93. As well, the Quick Ratio is 2.88, while the Cash Ratio is 0.75. Considering the valuation of this stock, the price to sales ratio is 4.19.
Transactions by insiders
Recent insider trading involved Hutson Nancy J, Director, that happened on Dec 13 ’24 when 7000.0 shares were sold. Director, Hutson Nancy J completed a deal on Dec 13 ’24 to buy 7000.0 shares. Meanwhile, Director McKee Amy E sold 8600.0 shares on Jun 24 ’24.
